Landscape → Oncology

Squamous Cell Carcinoma Clinical Trial Landscape

Data updated: May 20, 2026

630 clinical trials tracked since 2008

Squamous Cell Carcinoma is being studied across 630 clinical trials registered since 2008, with 304 programs currently active. The competitive pipeline includes 37 active Phase 3 trials, 227 active Phase 2 trials, and 89 active Phase 1 trials. Top industry sponsors include Regeneron, Merck, Replimune, Inc..

304 active

630 total (since 2008)

Phase 1 Active

217 total

227

Phase 2 Active

442 total

Phase 3 Active

62 total

Phase 4 Active

6 total

Top Industry Sponsors

Sorted by active Active Done Failed

Regeneron 2 5 2

Merck 2 2 0

Replimune, Inc. 2 0 0

Alentis Therapeutics AG 2 0 0

Ankyra Therapeutics, Inc 2 0 0

+ 10 more sponsors — see full table below

Featured Phase 3 Trials

NCT01810913 RECRUITING

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

National Cancer Institute (NCI) n=613

NCT06589804 RECRUITING

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

National Cancer Institute (NCI) n=158

NCT07061977 RECRUITING

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

National Cancer Institute (NCI) n=336

NCT05063552 ACTIVE NOT RECRUITING

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI) n=430

NCT03233711 ACTIVE NOT RECRUITING

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI) n=344

+ 57 more Phase 3 trials — see full database below

Squamous Cell Carcinoma — Trials Started by Year (last 10 years)

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

TheraRadar.com

Full Trial Database

Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.

Top Sponsors (all-time)

Regeneron

Merck

Replimune, Inc.

Alentis Therapeutics AG

Ankyra Therapeutics, Inc

Incyte Corporation

AstraZeneca

Privo Technologies

PDS Biotechnology Corp.

Oncolytics Biotech

Active Trials by Phase

Phase 1

Phase 2

227

Phase 3

Phase 4

Enrollment Size Distribution

1-50

344

51-200

174

201-500

501-1k

1k+

All Industry Sponsors

Sorted by active Active Done Failed

Regeneron 2 5 2

Merck 2 2 0

Replimune, Inc. 2 0 0

Alentis Therapeutics AG 2 0 0

Ankyra Therapeutics, Inc 2 0 0

Incyte Corporation 1 3 1

AstraZeneca 1 1 0

Privo Technologies 1 1 0

PDS Biotechnology Corp. 1 1 0

Oncolytics Biotech 1 1 0

Rakuten Medical, Inc. 1 0 1

Hummingbird Bioscience 1 0 0

Plexium, Inc. 1 0 0

EvolveImmune United, Inc 1 0 0

KaliVir Immunotherapeutics 1 0 0

NCT01810913 RECRUITING

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

National Cancer Institute (NCI) n=613

NCT06589804 RECRUITING

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

National Cancer Institute (NCI) n=158

NCT07061977 RECRUITING

National Cancer Institute (NCI) n=336

NCT05063552 ACTIVE NOT RECRUITING

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI) n=430

NCT03233711 ACTIVE NOT RECRUITING

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI) n=344

NCT06992427 RECRUITING

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

Alliance for Clinical Trials in Oncology n=228

NCT07573956 RECRUITING

Trial Evaluating Hypo-fractionated Accelerated Versus Conventional Fractionated Adjuvant RT in Head & Neck Malignancies

All India Institute of Medical Sciences n=369

NCT03801876 RECRUITING

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

NRG Oncology n=300

NCT05721755 ACTIVE NOT RECRUITING

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

ECOG-ACRIN Cancer Research Group n=290

NCT04333537 RECRUITING

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

NRG Oncology n=686

NCT03952585 ACTIVE NOT RECRUITING

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

National Cancer Institute (NCI) n=384

NCT04444921 ACTIVE NOT RECRUITING

EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients

National Cancer Institute (NCI) n=205

NCT00588770 ACTIVE NOT RECRUITING

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

National Cancer Institute (NCI) n=403

NCT06692556 RECRUITING

Study of a Strategy Integrating Adjuvant Radiation Therapy Versus Strategy Based on Monitoring in the Treatment of Carcinomas Spinocellular With High Risk of Recurrence

Centre Leon Berard n=266

NCT06563479 RECRUITING

A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer

Memorial Sloan Kettering Cancer Center n=291

NCT05893888 RECRUITING

A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers

Privo Technologies n=40

NCT06585410 RECRUITING

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

Regeneron Pharmaceuticals n=369

NCT07445048 RECRUITING

Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University n=370

NCT02466971 ACTIVE NOT RECRUITING

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

National Cancer Institute (NCI) n=450

NCT06790966 ACTIVE NOT RECRUITING

Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

PDS Biotechnology Corp. n=252

NCT07264075 RECRUITING

Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN

Groupe Oncologie Radiotherapie Tete et Cou n=780

NCT03969004 ACTIVE NOT RECRUITING

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Regeneron Pharmaceuticals n=415

NCT06030440 RECRUITING

De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

University of Erlangen-Nürnberg Medical School n=508

NCT01893307 ACTIVE NOT RECRUITING

Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients With Stage III-IVB Oropharyngeal Cancer

M.D. Anderson Cancer Center n=440

NCT07371611 RECRUITING

Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma

Qunxing Li,MD n=104

NCT04255849 ACTIVE NOT RECRUITING

Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV

Weill Medical College of Cornell University n=700

NCT07333274 RECRUITING

Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

Shandong Cancer Hospital and Institute n=335

NCT06115499 ACTIVE NOT RECRUITING

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

Alliance for Clinical Trials in Oncology n=10

NCT07311057 ENROLLING BY INVITATION

Investigation of Effect of Formulated Methylene Blue on Treatment of Squamous Cell Carcinoma Skin Cancer in Inoperable Patients and Not Suitable for Radiotherapy

Daryoush Hamidi Alamdari, PhD n=20

NCT05381597 RECRUITING

5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer

Boston University n=200

NCT05333523 RECRUITING

Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.

Radboud University Medical Center n=242

NCT05943795 ACTIVE NOT RECRUITING

A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

Sichuan Baili Pharmaceutical Co., Ltd. n=589

NCT02305654 RECRUITING

International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)

Institute of Cancer Research, United Kingdom n=200

NCT06258811 RECRUITING

Neoadjuvant Immunochemotherapy for LAOSCC

Lai-ping Zhong n=134

NCT06656091 NOT YET RECRUITING

A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma

Shanghai Runshi Pharmaceutical Technology Co., Ltd n=450

NCT05798793 RECRUITING

Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma

Hospital of Stomatology, Wuhan University n=309

NCT05125055 RECRUITING

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

Shanghai Jiao Tong University School of Medicine n=80

NCT06568172 SUSPENDED

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

National Cancer Institute (NCI) n=420

NCT05050162 SUSPENDED

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

NRG Oncology n=1,714

NCT03258554 COMPLETED

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI) n=196

NCT04472429 COMPLETED

Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

Incyte Corporation n=308

NCT04458909 TERMINATED

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

National Cancer Institute (NCI) n=15

NCT06513884 WITHDRAWN

A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer

Hookipa Biotech GmbH

NCT01101451 COMPLETED

Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery

GOG Foundation n=340

NCT03257267 COMPLETED

Study of Cemiplimab in Adults With Cervical Cancer

Regeneron Pharmaceuticals n=608

NCT03115476 TERMINATED

A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp

LEO Pharma n=563

NCT06781073 COMPLETED

Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma

Biotech Pharmaceutical Co., Ltd. n=118

NCT02923258 COMPLETED

Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University n=224

NCT02997553 COMPLETED

Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery

Institut de Cancérologie de Lorraine n=744

NCT03237325 COMPLETED

DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer

Soligenix n=266

NCT01414608 COMPLETED

Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer

GOG Foundation n=926

NCT01265849 COMPLETED

Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity

CEL-SCI Corporation n=928

NCT04196075 COMPLETED

The Effect of Andrographis Paniculata (AP) on Palliative Management of Advanced Esophageal Cancer

Chinese University of Hong Kong n=30

NCT01365156 COMPLETED

Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix

M.D. Anderson Cancer Center n=28

NCT02236936 TERMINATED

Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck

Arbeitsgemeinschaft medikamentoese Tumortherapie n=8

NCT04137627 COMPLETED

Melatonin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma

Indonesia University n=50

NCT01631357 COMPLETED

Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer

Tianjin Medical University Cancer Institute and Hospital n=96

NCT00803062 COMPLETED

Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

National Cancer Institute (NCI) n=452

NCT02765919 COMPLETED

A Randomised Controlled Trial Between Two Different HDR Brachytherapy Schedule in Locally Advanced Carcinoma of Uterine Cervix

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh n=30

NCT01542931 COMPLETED

TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma

Shanghai Jiao Tong University School of Medicine n=256

NCT01211938 COMPLETED

Trial Comparing Two Protocols of re Irradiation in an Irradiated Area for Carcinoma of the Upper Aerodigestive Tract

Gustave Roussy, Cancer Campus, Grand Paris n=60

NCT01161498 TERMINATED

Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer

BioVex Limited n=5

NCT05896839 RECRUITING

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

National Cancer Institute (NCI)

NCT05136196 RECRUITING

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

National Cancer Institute (NCI)

NCT04929028 ACTIVE NOT RECRUITING

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

NCT03866382 RECRUITING

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

NCT07281417 RECRUITING

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

NCT02133196 RECRUITING

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

NCT04858334 RECRUITING

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

National Cancer Institute (NCI)

NCT05172258 ACTIVE NOT RECRUITING

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

National Cancer Institute (NCI)

NCT07195734 RECRUITING

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

National Cancer Institute (NCI)

NCT02978625 ACTIVE NOT RECRUITING

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

National Cancer Institute (NCI)

NCT06702033 RECRUITING

The Minimalist Trial-2

Washington University School of Medicine

NCT07172256 RECRUITING

CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs

Yale University

NCT06980038 RECRUITING

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

National Cancer Institute (NCI)

NCT02834013 ACTIVE NOT RECRUITING

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

NCT07042295 RECRUITING

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

National Cancer Institute (NCI)

NCT05541016 RECRUITING

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

Mayo Clinic

NCT06041503 RECRUITING

Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

National Cancer Institute (NCI)

NCT02314169 ACTIVE NOT RECRUITING

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

National Cancer Institute (NCI)

NCT07149207 RECRUITING

Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors

Medical University of South Carolina

NCT07455331 NOT YET RECRUITING

Flash Radiotherapy for Skin Cancer

Jules Bordet Institute

NCT07578467 NOT YET RECRUITING

Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs

John Lukens

NCT07576725 NOT YET RECRUITING

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

Fred Hutchinson Cancer Center

NCT07484139 NOT YET RECRUITING

H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)

UNC Lineberger Comprehensive Cancer Center

NCT04502407 ACTIVE NOT RECRUITING

Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer

Cedars-Sinai Medical Center

NCT04671667 RECRUITING

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

National Cancer Institute (NCI)

NCT07062354 ENROLLING BY INVITATION

Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer

SWOG Cancer Research Network

NCT07058805 RECRUITING

Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer

Olgun Elicin

NCT05681039 RECRUITING

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

M.D. Anderson Cancer Center

NCT02734537 RECRUITING

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

ECOG-ACRIN Cancer Research Group

NCT03493425 RECRUITING

Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

ECOG-ACRIN Cancer Research Group

NCT04852328 RECRUITING

Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma

Washington University School of Medicine

NCT04430699 ACTIVE NOT RECRUITING

Cisplatin+Pembrolizumab+RT in Vulvar Cancer

Massachusetts General Hospital

NCT04166318 ACTIVE NOT RECRUITING

Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

ECOG-ACRIN Cancer Research Group

NCT06532279 RECRUITING

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

NRG Oncology

NCT06949800 NOT YET RECRUITING

CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial

University of California, San Francisco

NCT07405151 RECRUITING

A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)

Merck Sharp & Dohme LLC

NCT05714657 ACTIVE NOT RECRUITING

Shortened Course Adjuvant Radiotherapy Following TORS

Abramson Cancer Center at Penn Medicine

NCT07552558 NOT YET RECRUITING

Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

Washington University School of Medicine

NCT07419464 RECRUITING

5-Fluorouracil Response and Optimization STudy (The FROST Trial)

Washington University School of Medicine

NCT05108870 ACTIVE NOT RECRUITING

TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers

University of Chicago

NCT05268614 RECRUITING

Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma

University of Florida

NCT06161532 RECRUITING

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

National Cancer Institute (NCI)

NCT07209189 RECRUITING

Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT07115043 RECRUITING

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

AstraZeneca

NCT04349436 ACTIVE NOT RECRUITING

Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies

Replimune, Inc.

NCT07545083 NOT YET RECRUITING

Neoadjuvant Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC)

Shanghai Zhongshan Hospital

NCT01386385 ACTIVE NOT RECRUITING

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

NCT05969860 RECRUITING

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Mayo Clinic

NCT06731933 RECRUITING

Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin

Stanford University

NCT06567314 RECRUITING

Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma

M.D. Anderson Cancer Center

NCT07361133 NOT YET RECRUITING

Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer

National Cancer Institute, Egypt

NCT07223424 RECRUITING

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

Diwakar Davar

NCT07110038 RECRUITING

DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

NCT02128906 RECRUITING

Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Christopher Wilke

NCT05910827 RECRUITING

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

Hummingbird Bioscience

NCT04580771 ACTIVE NOT RECRUITING

A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial

M.D. Anderson Cancer Center

NCT07423078 RECRUITING

Window of Opportunity in Preserving Laryngeal Function Trial

Matthew Spector

NCT05307939 RECRUITING

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

Memorial Sloan Kettering Cancer Center

NCT06097468 RECRUITING

Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)

University of California, San Francisco

NCT03323463 ACTIVE NOT RECRUITING

Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma

Memorial Sloan Kettering Cancer Center

NCT05377905 RECRUITING

Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)

Falo, Louis, MD

NCT07513389 RECRUITING

Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)

Medical University of South Carolina

NCT07513324 NOT YET RECRUITING

Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)

Dana-Farber Cancer Institute

NCT07514767 NOT YET RECRUITING

Evaluation of the Efficacy and Safety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced Oral Squamous Cell Carcinoma

Prof. Lars Olaf Cardell

NCT05387915 ACTIVE NOT RECRUITING

Biomarker-Driven Radiation Therapy Dose Reduction After Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer

Emory University

NCT06137274 RECRUITING

Phase 2 Trial of Adaptive Radiotherapy Boost for HNSCC

H. Lee Moffitt Cancer Center and Research Institute

NCT05070403 RECRUITING

Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

NCT01898494 ACTIVE NOT RECRUITING

Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer

ECOG-ACRIN Cancer Research Group

NCT07497607 RECRUITING

Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma

Sara Medek

NCT06418724 NOT YET RECRUITING

Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma

Melanoma and Skin Cancer Trials Limited

NCT07189871 RECRUITING

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Radiopharm Theranostics, Ltd

NCT03410615 ACTIVE NOT RECRUITING

Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

Canadian Cancer Trials Group

NCT06323460 RECRUITING

Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer

Ohio State University Comprehensive Cancer Center

NCT04858269 RECRUITING

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

Wake Forest University Health Sciences

NCT07109726 RECRUITING

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Terremoto Biosciences Inc.

NCT07485296 RECRUITING

Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)

Gruppo Oncologico del Nord-Ovest

NCT05027633 RECRUITING

Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)

M.D. Anderson Cancer Center

NCT06876038 NOT YET RECRUITING

Low-cost Screening and Image-guided Photodynamic Therapy (PDT) of Premalignant and Malignant Oral Lesions

University of Massachusetts, Boston

NCT07169734 RECRUITING

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

Alentis Therapeutics AG

NCT05269381 RECRUITING

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Mayo Clinic

NCT06959082 RECRUITING

Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer

VSPharmTech Co.,Ltd.

NCT03074513 ACTIVE NOT RECRUITING

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

NCT06223659 RECRUITING

EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers

Ohio State University Comprehensive Cancer Center

NCT04712851 RECRUITING

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

Jonsson Comprehensive Cancer Center

NCT04030455 ACTIVE NOT RECRUITING

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

M.D. Anderson Cancer Center

NCT07228442 NOT YET RECRUITING

L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma

Philogen S.p.A.

NCT07457346 RECRUITING

A Study Testing Emactinib Sulfate With Chemotherapy and Immunotherapy Before Surgery for Advanced Head and Neck Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

NCT06050707 RECRUITING

MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach

University Health Network, Toronto

NCT00707473 ACTIVE NOT RECRUITING

Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

M.D. Anderson Cancer Center

NCT06627270 RECRUITING

Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer

Case Comprehensive Cancer Center

NCT06747585 RECRUITING

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

Alentis Therapeutics AG

NCT04988074 RECRUITING

Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT06047379 RECRUITING

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

NCT05639972 RECRUITING

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Christian Hinrichs

NCT05686226 RECRUITING

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Christian Hinrichs

NCT07435376 RECRUITING

Intra-lesional Tumor Boost for Bulky Cervical Cancer

Seoul National University Bundang Hospital

NCT07044635 RECRUITING

Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.

University of Utah

NCT05888844 ACTIVE NOT RECRUITING

A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma

Incyte Corporation

NCT07428148 NOT YET RECRUITING

Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell Carcinoma

NYU Langone Health

NCT07425054 NOT YET RECRUITING

HPV ctDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Advanced-Stage Anal Cancer

Jennifer Dorth

NCT07063212 RECRUITING

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

Memorial Sloan Kettering Cancer Center

NCT04150900 ACTIVE NOT RECRUITING

1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck

University of Maryland, Baltimore

NCT04675710 ACTIVE NOT RECRUITING

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

M.D. Anderson Cancer Center

NCT07418034 NOT YET RECRUITING

A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)

University of Maryland, Baltimore

NCT06041802 ACTIVE NOT RECRUITING

A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)

Merck Sharp & Dohme LLC

NCT06995508 RECRUITING

Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial

Roswell Park Cancer Institute

NCT04171622 ACTIVE NOT RECRUITING

Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

M.D. Anderson Cancer Center

NCT07288073 RECRUITING

TIL Therapy in cSCC and MCC

Karam Khaddour, MD, MS

NCT03085147 ACTIVE NOT RECRUITING

A Dye for the Detection of Cancer of the Tongue and Mouth

Memorial Sloan Kettering Cancer Center

NCT06636734 RECRUITING

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

Emory University

NCT04862650 ACTIVE NOT RECRUITING

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Marcelo Bonomi

NCT07392580 NOT YET RECRUITING

Intralesional Chemotherapy (IC): Cisplatin + Epinephrine

University of Miami

NCT07394244 NOT YET RECRUITING

Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma

Fudan University

NCT03944941 ACTIVE NOT RECRUITING

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

Alliance for Clinical Trials in Oncology

NCT05962242 RECRUITING

HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma

University of Virginia

NCT03260023 ACTIVE NOT RECRUITING

Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

Transgene

NCT05737199 ACTIVE NOT RECRUITING

Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma

Niigata University Medical & Dental Hospital

NCT06485778 RECRUITING

A Study of Radiation Therapy After Surgery in People With Oral Tongue Squamous Cell Carcinoma

Memorial Sloan Kettering Cancer Center

NCT05894083 RECRUITING

A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)

University of Michigan Rogel Cancer Center

NCT06319963 RECRUITING

A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer

Theravectys S.A.

NCT07214987 NOT YET RECRUITING

PDT For Induction Therapy For Head And Neck Cancer

Massachusetts General Hospital

NCT02721732 ACTIVE NOT RECRUITING

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

M.D. Anderson Cancer Center

NCT07370337 RECRUITING

Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal

Eye & ENT Hospital of Fudan University

NCT07368985 NOT YET RECRUITING

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

Prof. Dr. Remi A. Nout

NCT03386500 ACTIVE NOT RECRUITING

Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer

University of Nebraska

NCT03468218 ACTIVE NOT RECRUITING

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

Emory University

NCT07346196 NOT YET RECRUITING

A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck

University of Chicago

NCT07346807 NOT YET RECRUITING

Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer

Shanghai Zhongshan Hospital

NCT05312710 ACTIVE NOT RECRUITING

Safety and Efficacy of APG-157 in Head and Neck Cancer

Aveta Biomics, Inc.

NCT07339176 RECRUITING

Intratumoral N17350 in Advanced Solid Tumors

Onchilles Pharma Inc

NCT06831149 RECRUITING

Use of SPY Imaging System to Minimize Fistulas After Hypopharyngeal Reconstruction

Matthew Spector

NCT03215719 RECRUITING

Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma

NYU Langone Health

NCT05858229 ACTIVE NOT RECRUITING

Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1.

Sherrif Ibrahim

NCT06640283 RECRUITING

Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes

Instituto do Cancer do Estado de São Paulo

NCT07285044 RECRUITING

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Mayo Clinic

NCT06121505 RECRUITING

Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer

Sichuan University

NCT06288191 RECRUITING

Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma

Melanoma Institute Australia

NCT07280377 ACTIVE NOT RECRUITING

A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

Oncolytics Biotech

NCT06104618 RECRUITING

Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis

Mayo Clinic

NCT06353906 RECRUITING

Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer

The Netherlands Cancer Institute

NCT05120271 ACTIVE NOT RECRUITING

BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

Sotio Biotech Inc.

NCT06448026 RECRUITING

Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).

M.D. Anderson Cancer Center

NCT07094685 RECRUITING

Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer

University of Michigan Rogel Cancer Center

NCT06364384 RECRUITING

Radical Concurrent Chemoradiotherapy With DDP/5-FU and PD-1 Antibody for Non-metastatic Rectal Squamous Cell Carcinoma

Sixth Affiliated Hospital, Sun Yat-sen University

NCT03449108 ACTIVE NOT RECRUITING

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

NCT04315701 ACTIVE NOT RECRUITING

A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer

University of Southern California

NCT04759911 ACTIVE NOT RECRUITING

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

M.D. Anderson Cancer Center

NCT06088381 RECRUITING

Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)

University of Maryland, Baltimore

NCT05565417 ACTIVE NOT RECRUITING

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

Immunitas Therapeutics

NCT04370587 RECRUITING

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

ImmVira Pharma Co. Ltd

NCT05996523 ACTIVE NOT RECRUITING

Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer

National Cancer Institute (NCI)

NCT05582122 RECRUITING

SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers

UNICANCER

NCT07180576 NOT YET RECRUITING

The FORCE Trial Pilot: Fish Oil-enriched Nutrition for Radiotherapy in Cancer of the hEad and Neck

Anna Arthur, PhD

NCT07010692 RECRUITING

Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment

Bruce Robinson, MD

NCT07147426 NOT YET RECRUITING

Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo)

Tianjin Medical University Cancer Institute and Hospital

NCT07145931 NOT YET RECRUITING

Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base

Sun Yat-sen University

NCT07137858 NOT YET RECRUITING

Adebrelimab Combined With Carboplatin and Albumin-bound Taxanol in the Treatment of Resectable Locally Advanced Oral Squamous Cell Carcinoma Cardiac, Randomized, Phase II Exploratory Study

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

NCT07135804 NOT YET RECRUITING

Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma

Second Affiliated Hospital of Nanchang University

NCT06543576 RECRUITING

External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer

Jonsson Comprehensive Cancer Center

NCT07121595 RECRUITING

Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial

University of Michigan Rogel Cancer Center

NCT05574101 ACTIVE NOT RECRUITING

A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer

Memorial Sloan Kettering Cancer Center

NCT04900623 RECRUITING

Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study

Jonathan Schoenfeld, MD, MPH

NCT04609280 ACTIVE NOT RECRUITING

Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110)

University of Maryland, Baltimore

NCT05756569 RECRUITING

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Emory University

NCT07079410 NOT YET RECRUITING

Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma

Shanghai Zhongshan Hospital

NCT05423197 NOT YET RECRUITING

89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC

Stanford University

NCT06990737 RECRUITING

Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck

University of California, Davis

NCT05086692 RECRUITING

A Beta-only IL-2 ImmunoTherapY Study

Medicenna Therapeutics, Inc.

NCT05286294 ACTIVE NOT RECRUITING

Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders

Oslo University Hospital

NCT07007364 RECRUITING

Neoadjuvant Low-Dose Radiotherapy Combined With Adebrelimab and Single-Agent Albumin-Bound Paclitaxel Chemotherapy for Early-Stage Oral Squamous Cell Carcinoma: A Prospective, Single-Arm Clinical Trial

Jun Jia

NCT06940180 RECRUITING

Toripalimab With Chemotherapy for Sinus Cancer

Glenn J. Hanna

NCT04305795 ACTIVE NOT RECRUITING

An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

Rakuten Medical, Inc.

NCT05419089 RECRUITING

The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial)

Icahn School of Medicine at Mount Sinai

NCT03854032 ACTIVE NOT RECRUITING

Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck

Thomas Jefferson University

NCT06009861 ACTIVE NOT RECRUITING

Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)

Peking University Hospital of Stomatology

NCT06998342 NOT YET RECRUITING

MOHs Surgery and Short-Course Radiation Therapy With Structured Follow-Up for Head & Neck Squamous Cell Skin Cancer

University of Vermont Medical Center

NCT06823479 RECRUITING

Towards Cure Via Only Ultra-short ICB in CSCC

The Netherlands Cancer Institute

NCT04808999 ACTIVE NOT RECRUITING

Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)

Diwakar Davar

NCT05144698 RECRUITING

RAPA-201 Therapy of Solid Tumors

Rapa Therapeutics LLC

NCT06861712 NOT YET RECRUITING

Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer

Sun Yat-sen University

NCT04802876 ACTIVE NOT RECRUITING

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors

SOLTI Breast Cancer Research Group

NCT06876844 RECRUITING

Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

NCT04632433 ACTIVE NOT RECRUITING

Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma

Fondazione Melanoma Onlus

NCT04191460 RECRUITING

Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer

Erasmus Medical Center

NCT05752149 NOT YET RECRUITING

Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial

Erasmus Medical Center

NCT04943445 ACTIVE NOT RECRUITING

Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers

Latin American Cooperative Oncology Group

NCT06797986 NOT YET RECRUITING

A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects with HPV Positive HNSCC.

Cellid Co., Ltd.

NCT03708224 RECRUITING

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Alain Algazi

NCT04050436 ACTIVE NOT RECRUITING

Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer

Replimune, Inc.

NCT05202860 ACTIVE NOT RECRUITING

Impact of Human Papillomavirus (HPV) Vaccination on Burden of Disease in Patients with Actinic Keratosis

Merete Haedersdal

NCT06759155 NOT YET RECRUITING

Phase II Clinical Trial of De-Intensified Therapy in Human Papilloma Virus (HPV) Associated Oropharyngeal Squamous Cell Carcinoma

University of Vermont Medical Center

NCT06752798 RECRUITING

Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCC

Hunan Cancer Hospital

NCT04719988 ACTIVE NOT RECRUITING

Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.

Centre Hospitalier Universitaire de Besancon

NCT06016920 RECRUITING

Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma

Nykode Therapeutics ASA

NCT06728618 NOT YET RECRUITING

Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma

Shanghai Zhongshan Hospital

NCT05878288 ACTIVE NOT RECRUITING

Deep sequencIng in Cutaneous Squamous CEll caRciNomas

Peter MacCallum Cancer Centre, Australia

NCT05620134 ACTIVE NOT RECRUITING

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Salubris Biotherapeutics Inc

NCT06137378 RECRUITING

European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]

University of Leipzig

NCT04718415 ACTIVE NOT RECRUITING

Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

NCT06578871 NOT YET RECRUITING

Surgery and Reducing Ionizing Radiation of the Unknown Primary

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

NCT06577311 RECRUITING

Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis)

The Center for Clinical and Cosmetic Research

NCT06505551 NOT YET RECRUITING

Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma

SCG Cell Therapy Pte. Ltd.

NCT03784066 ACTIVE NOT RECRUITING

Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity

Universitaire Ziekenhuizen KU Leuven

NCT03283605 ACTIVE NOT RECRUITING

Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas

Centre hospitalier de l'Université de Montréal (CHUM)

NCT04444869 RECRUITING

Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer

University of Missouri-Columbia

NCT04204837 RECRUITING

Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin

Salzburger Landeskliniken

NCT05905315 RECRUITING

Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For LAVC

The Netherlands Cancer Institute

NCT05098119 RECRUITING

Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

NCT04889742 NOT YET RECRUITING

Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors

Charite University, Berlin, Germany

NCT04894370 RECRUITING

Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma

Centre Hospitalier Universitaire de Besancon

NCT05069857 RECRUITING

Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients

Shanghai Jiao Tong University School of Medicine

NCT05661188 RECRUITING

Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)

Grupo Espanol Multidisciplinario del Cancer Digestivo

NCT05862168 RECRUITING

Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial

Weijia Fang, MD

NCT04192253 RECRUITING

Treatment of Locally Advanced VULvar CArcinoma in a Neoadjuvant Setting With Carboplatin and Paclitaxel Chemotherapy (VULCANize)

The Netherlands Cancer Institute

NCT04161664 RECRUITING

Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy

The Netherlands Cancer Institute

NCT04018872 RECRUITING

Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer

Dallas VA Medical Center

NCT04220749 RECRUITING

Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

NCT04369937 COMPLETED

HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma

Dan Zandberg

NCT02296684 COMPLETED

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

Washington University School of Medicine

NCT03799445 TERMINATED

Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma

M.D. Anderson Cancer Center

NCT03621696 COMPLETED

Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)"

Washington University School of Medicine

NCT02437851 COMPLETED

Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection

AIDS Malignancy Consortium

NCT03476330 COMPLETED

Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia

Children's Hospital Medical Center, Cincinnati

NCT04799054 TERMINATED

A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

Ascendis Pharma Oncology Division A/S

NCT03370276 COMPLETED

Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

NCT06036836 COMPLETED

Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

Merck Sharp & Dohme LLC

NCT00939627 COMPLETED

Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab

National Cancer Institute (NCI)

NCT05316688 TERMINATED

A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery

University of Washington

NCT03786237 COMPLETED

Rigosertib for RDEB-SCC

Prof. Johann Bauer

NCT05419479 SUSPENDED

Switch Maintenance in Pancreatic

James Cleary, MD, PhD

NCT01932697 COMPLETED

Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer

Mayo Clinic

NCT05551117 TERMINATED

A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

MacroGenics

NCT04913220 TERMINATED

A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

Sanofi

NCT03082534 COMPLETED

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

University of California, San Diego

NCT03829722 COMPLETED

Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer

University of Michigan Rogel Cancer Center

NCT04260802 TERMINATED

A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Ocellaris Pharma, Inc.

NCT04031534 COMPLETED

Study of Hypoxia Measured in F-Miso PET/Scan and MRI in Patients With Squamous Cells Carcinoma

Centre Henri Becquerel

NCT04154943 COMPLETED

Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma

Regeneron Pharmaceuticals

NCT04445064 TERMINATED

Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

NCT04916002 TERMINATED

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Regeneron Pharmaceuticals

NCT02369458 COMPLETED

Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies

Washington University School of Medicine

NCT05256381 TERMINATED

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

SOTIO Biotech AG

NCT03021993 COMPLETED

Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer

Medical University of South Carolina

NCT03901573 TERMINATED

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

NeoImmuneTech

NCT02254278 COMPLETED

Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer

NRG Oncology

NCT04260126 COMPLETED

Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC

PDS Biotechnology Corp.

NCT05104567 COMPLETED

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)

Sanofi

NCT04180215 COMPLETED

A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Hookipa Biotech GmbH

NCT03597295 COMPLETED

A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)

Incyte Corporation

NCT06762808 WITHDRAWN

Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC

M.D. Anderson Cancer Center

NCT04620200 COMPLETED

Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery

The Netherlands Cancer Institute

NCT03623646 COMPLETED

Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial.

Institut Claudius Regaud

NCT07038915 WITHDRAWN

STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1

M.D. Anderson Cancer Center

NCT03795610 COMPLETED

IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma

Assuntina G. Sacco, MD

NCT05714553 TERMINATED

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

NuCana plc

NCT03737721 TERMINATED

The UNSCARRed Study: UNresctable Squamous Cell Carcinoma Treated With Avelumab and Radical Radiotherapy

AHS Cancer Control Alberta

NCT03357757 COMPLETED

Avelumab With Valproic Acid in Virus-associated Cancer

AHS Cancer Control Alberta

NCT04068896 COMPLETED

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

NGM Biopharmaceuticals, Inc

NCT03108131 COMPLETED

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

M.D. Anderson Cancer Center

NCT02760498 COMPLETED

Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Regeneron Pharmaceuticals

NCT04442126 TERMINATED

A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

Numab Therapeutics AG

NCT03944915 COMPLETED

De-Escalation Therapy for Human Papillomavirus Negative Disease

University of Chicago

NCT04329221 WITHDRAWN

Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

Massachusetts General Hospital

NCT04642287 WITHDRAWN

Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

Massachusetts General Hospital

NCT03107182 COMPLETED

Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer

University of Chicago

NCT06644079 WITHDRAWN

Window of Opportunity Study of Topical Tranexamic Acid for Cutaneous Squamous Cell Carcinoma

University of Florida

NCT04595981 WITHDRAWN

Chemo-embolization for Head and Neck Cancer

University of Alabama at Birmingham

NCT03342911 COMPLETED

Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

NCT04339062 COMPLETED

Cemiplimab in AlloSCT/SOT Recipients With CSCC

Dana-Farber Cancer Institute

NCT03267680 TERMINATED

IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

University of Southern California

NCT05608369 WITHDRAWN

Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC

Case Comprehensive Cancer Center

NCT03058289 COMPLETED

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

Intensity Therapeutics, Inc.

NCT03721757 COMPLETED

CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer

The Clatterbridge Cancer Centre NHS Foundation Trust

NCT03190174 COMPLETED

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

Sarcoma Oncology Research Center, LLC

NCT06159842 COMPLETED

Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC)

The Center for Clinical and Cosmetic Research

NCT04812535 TERMINATED

Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.

InflaRx GmbH

NCT04710498 COMPLETED

Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma

Stanford University

NCT03715946 COMPLETED

Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer

Robert L. Ferris, MD, PhD

NCT04649476 COMPLETED

Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma

Hospital of Stomatology, Wuhan University

NCT03719924 COMPLETED

Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma

Federation Francophone de Cancerologie Digestive

NCT05007613 COMPLETED

Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

National Taiwan University Hospital

NCT04807777 TERMINATED

Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma

Columbia University

NCT05060471 COMPLETED

PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients

Sun Yat-sen University

NCT02538510 COMPLETED

Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery

University of Washington

NCT03714828 COMPLETED

Study of TVEC in Patients With Cutaneous Squamous Cell Cancer

University of Arizona

NCT02258659 COMPLETED

Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer

University of Chicago

NCT03422536 COMPLETED

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

University of Arizona

NCT04944173 WITHDRAWN

SCION: SABR and Checkpoint Inhibition of NSCLC

University of British Columbia

NCT03284424 COMPLETED

Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)

Merck Sharp & Dohme LLC

NCT03387111 TERMINATED

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

ImmunityBio, Inc.

NCT03423264 WITHDRAWN

PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing

University of Chicago

NCT06384820 WITHDRAWN

Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)

Regeneron Pharmaceuticals

NCT06084845 WITHDRAWN

Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer

ECOG-ACRIN Cancer Research Group

NCT01064479 COMPLETED

Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

M.D. Anderson Cancer Center

NCT02383927 COMPLETED

Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

Kura Oncology, Inc.

NCT04541355 COMPLETED

Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin

Hyunseok Kang, MD

NCT02964559 COMPLETED

Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer

Emory University

NCT03847519 COMPLETED

Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

Advaxis, Inc.

NCT03494322 COMPLETED

EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer

University College, London

NCT03601507 TERMINATED

Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer

University of Arizona

NCT04844983 COMPLETED

A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC

Sirnaomics

NCT03339843 COMPLETED

Multiorgan Metabolic Imaging Response Assessment of Abemaciclib

Jules Bordet Institute

NCT04410874 TERMINATED

Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer

Ivan Litvinov

NCT02830594 COMPLETED

Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer

City of Hope Medical Center

NCT02609386 COMPLETED

IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity

Brooklyn ImmunoTherapeutics, LLC

NCT01485809 COMPLETED

Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy

Seoul Veterans Hospital

NCT03618134 TERMINATED

Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

Jonsson Comprehensive Cancer Center

NCT02831933 TERMINATED

Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma

Eric Bernicker, MD

NCT05535023 WITHDRAWN

Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma

M.D. Anderson Cancer Center

NCT03912818 TERMINATED

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Stanford University

NCT00707655 TERMINATED

Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy

Genmab

NCT03690921 COMPLETED

Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial

M.D. Anderson Cancer Center

NCT05582031 WITHDRAWN

Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers

Translational Research in Oncology

NCT03769311 COMPLETED

Cetuximab in Head and Neck Cancer Patients

University of Wisconsin, Madison

NCT03802058 TERMINATED

Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer

Wuhan University

NCT04611321 TERMINATED

Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Innovent Biologics (Suzhou) Co. Ltd.

NCT02917629 TERMINATED

ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment

National Cancer Institute (NCI)

NCT02921269 COMPLETED

Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer

National Cancer Institute (NCI)

NCT02213133 TERMINATED

Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas

Karyopharm Therapeutics Inc

NCT01341535 COMPLETED

Comparison of Adaptive Dose Painting by Numbers With Standard Radiotherapy for Head and Neck Cancer.

University Hospital, Ghent

NCT03762564 COMPLETED

Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior Therapy

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

NCT01693783 COMPLETED

Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer

National Cancer Institute (NCI)

NCT01088802 COMPLETED

Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT04242173 TERMINATED

Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC

H. Lee Moffitt Cancer Center and Research Institute

NCT03502148 COMPLETED

Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma

Privo Technologies

NCT02218164 COMPLETED

Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

NCT02002182 COMPLETED

ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer

Andrew Sikora

NCT01592721 COMPLETED

Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma

The University of Texas Health Science Center at San Antonio

NCT04985825 WITHDRAWN

Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Pega-One S.A.S.

NCT01212822 COMPLETED

Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer

Fox Chase Cancer Center

NCT01220752 COMPLETED

Treatment of Malignant Sinonasal Tumours With Intensity-modulated Radiotherapy (IMRT) and Carbon Ion Boost (C12)

Heidelberg University

NCT04831450 WITHDRAWN

Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)

University of Miami

NCT04001413 WITHDRAWN

Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT00573131 TERMINATED

Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer

Boston Scientific Corporation

NCT03834571 WITHDRAWN

Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women

AIDS Malignancy Consortium

NCT02837042 TERMINATED

Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma

University of Alabama at Birmingham

NCT04293679 COMPLETED

Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC

Sirnaomics

NCT03090412 TERMINATED

Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer

Roswell Park Cancer Institute

NCT01884259 COMPLETED

Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN

Arbeitsgemeinschaft medikamentoese Tumortherapie

NCT04625543 WITHDRAWN

Neoadjuvant Immunotherapy to ESCC

Qilu Hospital of Shandong University

NCT03684785 TERMINATED

Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors

Exicure, Inc.

NCT02417701 COMPLETED

Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer

National Cancer Institute (NCI)

NCT02873819 COMPLETED

Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity

Gliknik Inc.

NCT03430895 COMPLETED

Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

Memorial Sloan Kettering Cancer Center

NCT04499352 WITHDRAWN

A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer

Boehringer Ingelheim

NCT01816984 COMPLETED

PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

University of Chicago

NCT03875859 TERMINATED

Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC)

Kavita Sarin

NCT01077999 COMPLETED

Chemoradiation and Panitumumab for Esophageal Cancer

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

NCT02394652 COMPLETED

The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial

University Health Network, Toronto

NCT00896181 COMPLETED

Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)

Stanford University

NCT01414426 COMPLETED

Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions

University of Chicago

NCT04267913 WITHDRAWN

Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

NCT02319044 COMPLETED

Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

AstraZeneca

NCT01266460 COMPLETED

Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer

Gynecologic Oncology Group

NCT02776137 COMPLETED

Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and Neck

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

NCT02347813 COMPLETED

Preventing Squamous Cell Skin Cancer

University of Rochester

NCT01198028 COMPLETED

Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma

M.D. Anderson Cancer Center

NCT02017600 TERMINATED

A Phase II Trial of Induction Chemotherapy With ND-420, Cisplatin and Fluorouracil Followed by Surgery in the Treatment of Patients With Localized Squamous Cell Carcinoma of the Esophagus

Nang Kuang Pharmaceutical Co., Ltd.

NCT01192815 TERMINATED

Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck

Case Comprehensive Cancer Center

NCT02541903 TERMINATED

Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma

University of Alabama at Birmingham

NCT01044433 COMPLETED

Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck

Abramson Cancer Center at Penn Medicine

NCT02624999 WITHDRAWN

Study Comparing AlloVax™ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck

Mirror Biologics, Inc.

NCT01806675 COMPLETED

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

Sanjiv Sam Gambhir

NCT01266447 COMPLETED

Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer

National Cancer Institute (NCI)

NCT01611662 TERMINATED

Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer

Fox Chase Cancer Center

NCT02713828 TERMINATED

Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung

PrECOG, LLC.

NCT01248299 TERMINATED

Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.

Centre Oscar Lambret

NCT02123511 COMPLETED

Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy

Mayo Clinic

NCT02706691 TERMINATED

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

University of Chicago

NCT01267253 COMPLETED

Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer

Gynecologic Oncology Group

NCT00652080 COMPLETED

An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS)

BPGbio

NCT01181401 COMPLETED

InductionChemo-Radio-Antibody-Treatment

Charite University, Berlin, Germany

NCT03223662 TERMINATED

Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy

National Cancer Institute (NCI)

NCT01941992 COMPLETED

Role of SAMITAL® in the Relief of Chemo-radiation (CT-RT) Induced Oral Mucositis in Head and Neck Cancer Patients

Istituto Oncologico Veneto IRCCS

NCT02048020 COMPLETED

Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer

Jonsson Comprehensive Cancer Center

NCT02644122 TERMINATED

SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes

Ezra Cohen

NCT01285778 COMPLETED

Vectibix for the Treatment of Anal Cancer

Grupo Espanol Multidisciplinario del Cancer Digestivo

NCT01823679 TERMINATED

Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin

Stanford University

NCT01642082 COMPLETED

Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer

Gynecologic Oncology Group

NCT01316757 COMPLETED

Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Fox Chase Cancer Center

NCT01612546 COMPLETED

Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery

City of Hope Medical Center

NCT01984892 TERMINATED

Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)

Nina Bhardwaj

NCT03307941 WITHDRAWN

Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA

Jules Bordet Institute

NCT01178944 COMPLETED

Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer

Roswell Park Cancer Institute

NCT00888173 COMPLETED

Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Gynecologic Oncology Group

NCT01349933 COMPLETED

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

National Cancer Institute (NCI)

NCT02298595 WITHDRAWN

Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

Julie E. Bauman, MD, MPH

NCT02076243 TERMINATED

Treatment With Nab-paclitaxel in Cutaneous SCC

Icahn School of Medicine at Mount Sinai

NCT02068157 TERMINATED

Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer

Roswell Park Cancer Institute

NCT01225887 COMPLETED

Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Gynecologic Oncology Group

NCT01807546 COMPLETED

Oral Rigosertib for Squamous Cell Carcinoma

Traws Pharma, Inc.

NCT00895245 TERMINATED

Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy

University of Washington

NCT01794845 TERMINATED

Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma

University of Miami

NCT02196168 TERMINATED

Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

National Cancer Institute (NCI)

NCT01267240 TERMINATED

Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

National Cancer Institute (NCI)

NCT01256385 COMPLETED

Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy

National Cancer Institute (NCI)

NCT02331875 TERMINATED

Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity

Innate Pharma

NCT02007200 COMPLETED

Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery

National Cancer Institute (NCI)

NCT02279576 TERMINATED

Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG)

Spanish Oncology Genito-Urinary Group

NCT02562729 COMPLETED

Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer

Shanghai Gynecologic Oncology Group

NCT01639625 COMPLETED

Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application

Laboratorio Elea Phoenix S.A.

NCT01129206 COMPLETED

Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy

Ohio State University Comprehensive Cancer Center

NCT01108042 COMPLETED

TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer

Orlando Guntinas-Lichius, Prof. Dr. med.

NCT02059252 TERMINATED

Safety, Tolerability and Performance of SmartMatrix Dermal Replacement Scaffold

Smart Matrix Limited

NCT00998192 COMPLETED

A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung

Oncolytics Biotech

NCT02014831 WITHDRAWN

Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE)

Centre Leon Berard

NCT01287390 COMPLETED

Adaptive, Image-guided, Intensity-modulated Radiotherapy for Head and Neck Cancer in the Reduced Volumes of Elective Neck

University Hospital, Ghent

NCT02042885 TERMINATED

A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer

Otsuka Novel Products GmbH

NCT01026792 COMPLETED

Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery

National Cancer Institute (NCI)

NCT01586182 WITHDRAWN

Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma

Dana-Farber Cancer Institute

NCT01192204 COMPLETED

Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention

Ohio State University

NCT01009203 TERMINATED

Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma

New Mexico Cancer Research Alliance

NCT01953952 WITHDRAWN

Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage III-IV Oropharyngeal Cancer

Radiation Therapy Oncology Group

NCT02033538 WITHDRAWN

Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of Esophagus

Zhejiang University

NCT02041819 WITHDRAWN

Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus

Zhejiang University

NCT01333852 TERMINATED

Metformin Plus Paclitaxel for Metastatic or Recurrent Head and Neck Cancer

Lucas Vieira dos Santos

NCT01666431 TERMINATED

Single-center Investigator Initiated Pilot Study Investigating the Tumor Response of Squamous Cell Carcinoma Lesions in Patients Under Lapatinib Treatment

University of Zurich

NCT01133665 COMPLETED

Cetuximab and Lenalidomide in Head and Neck

University of Chicago

NCT01465815 WITHDRAWN

Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)

OHSU Knight Cancer Institute

NCT01682031 TERMINATED

Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy

Roswell Park Cancer Institute

NCT01561456 COMPLETED

Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung

Axelar AB

NCT01596868 COMPLETED

GP VS TP in the Treatment of Advanced Nasopharyngeal Carcinoma in Northwest China

Air Force Military Medical University, China

NCT01674374 WITHDRAWN

Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy

Roswell Park Cancer Institute

NCT01382745 TERMINATED

Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers

Dr. Te Vuong

NCT00605709 WITHDRAWN

Dose-Ranging Safety and Efficacy Study of Topical Creams Containing API 31510 for the Treatment of in Situ Cutaneous Squamous Cell Carcinoma

BPGbio

NCT05172245 RECRUITING

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

National Cancer Institute (NCI)

NCT07156227 NOT YET RECRUITING

Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma

National Cancer Institute (NCI)

NCT02496208 ACTIVE NOT RECRUITING

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

National Cancer Institute (NCI)

NCT06747390 RECRUITING

Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery

Ryan Carey

NCT07217028 RECRUITING

Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma

Vanderbilt-Ingram Cancer Center

NCT07565740 RECRUITING

Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC

West China Hospital

NCT03816332 ACTIVE NOT RECRUITING

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

National Cancer Institute (NCI)

NCT02595879 ACTIVE NOT RECRUITING

Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer

National Cancer Institute (NCI)

NCT03803774 ACTIVE NOT RECRUITING

Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma

National Cancer Institute (NCI)

NCT03114462 RECRUITING

Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

M.D. Anderson Cancer Center

NCT07284186 RECRUITING

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

Plexium, Inc.

NCT04533750 ACTIVE NOT RECRUITING

Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

NCT07217171 RECRUITING

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

EvolveImmune United, Inc

NCT06444815 RECRUITING

A Study of VET3-TGI in Patients With Solid Tumors

KaliVir Immunotherapeutics

NCT06236425 ACTIVE NOT RECRUITING

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

H. Lee Moffitt Cancer Center and Research Institute

NCT07460765 NOT YET RECRUITING

Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

Vanderbilt-Ingram Cancer Center

NCT06171750 RECRUITING

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

Ankyra Therapeutics, Inc

NCT06868433 RECRUITING

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Emory University

NCT06014086 ACTIVE NOT RECRUITING

Intratumoral PH-762 for Cutaneous Carcinoma

Phio Pharmaceuticals Inc.

NCT07390838 RECRUITING

A Study of SH009 Injection in Patients With Advanced Solid Tumors.

Nanjing Sanhome Pharmaceutical, Co., Ltd.

NCT04754321 RECRUITING

Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer

Ohio State University Comprehensive Cancer Center

NCT04391049 ACTIVE NOT RECRUITING

Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery

NRG Oncology

NCT07335380 NOT YET RECRUITING

Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma

NYU Langone Health

NCT05085496 RECRUITING

Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC

City of Hope Medical Center

NCT06997094 RECRUITING

Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer

Mayo Clinic

NCT05827614 ACTIVE NOT RECRUITING

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

Boundless Bio, Inc.

NCT06736379 RECRUITING

Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer

VLP Therapeutics

NCT04616248 ACTIVE NOT RECRUITING

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

University of Southern California

NCT06999187 RECRUITING

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Dren Bio

NCT07275073 RECRUITING

JMT106 Injection in the Treatment of Advanced Solid Tumors

Shanghai JMT-Bio Inc.

NCT04975152 ACTIVE NOT RECRUITING

Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

NCT02567422 ACTIVE NOT RECRUITING

Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer

National Cancer Institute (NCI)

NCT05859074 RECRUITING

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Memorial Sloan Kettering Cancer Center

NCT06912087 RECRUITING

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

University of Chicago

NCT03983954 ACTIVE NOT RECRUITING

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

NeoTX Therapeutics Ltd.

NCT05973487 ACTIVE NOT RECRUITING

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

TScan Therapeutics, Inc.

NCT05076760 RECRUITING

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

Memgen, Inc.

NCT04429542 RECRUITING

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Bicara Therapeutics

NCT04428671 RECRUITING

Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer

Emory University

NCT07100925 NOT YET RECRUITING

A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma

Ankyra Therapeutics, Inc

NCT05540899 ACTIVE NOT RECRUITING

Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer

American College of Radiology

NCT06005324 RECRUITING

Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer

University of Chicago

NCT03212404 ACTIVE NOT RECRUITING

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Checkpoint Therapeutics, Inc.

NCT04576091 ACTIVE NOT RECRUITING

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

National Cancer Institute (NCI)

NCT06610071 NOT YET RECRUITING

NIFR Image-guided Surgery for Malignant Soft Tissue Tumor With Low-dose SWIG Technique

The Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

NCT06589609 RECRUITING

Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer

BlueSky Immunotherapies GmbH

NCT05582590 NOT YET RECRUITING

Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers

NexImmune Inc.

NCT07600476 RECRUITING

A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors

Kupando GmbH

NCT03114319 TERMINATED

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

Novartis Pharmaceuticals

NCT02819752 TERMINATED

PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck

Royal Marsden NHS Foundation Trust

NCT04234113 TERMINATED

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

SOTIO Biotech AG

NCT06560645 TERMINATED

A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

Prelude Therapeutics

NCT04163952 TERMINATED

Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin

Rutgers, The State University of New Jersey

NCT03978689 COMPLETED

A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

Cue Biopharma

NCT03889912 COMPLETED

Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma

Regeneron Pharmaceuticals

NCT03381183 COMPLETED

IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

NCT03738228 COMPLETED

Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer

National Cancer Institute (NCI)

NCT04272034 TERMINATED

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

Incyte Corporation

NCT02586207 COMPLETED

Pembrolizumab in Combination With CRT for LA-SCCHN

Sanford Health

NCT04000529 TERMINATED

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Novartis Pharmaceuticals

NCT00954226 COMPLETED

Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer

M.D. Anderson Cancer Center

NCT02013154 COMPLETED

A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab

Leap Therapeutics, Inc.

NCT04242199 COMPLETED

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

Incyte Corporation

NCT04152018 TERMINATED

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Pfizer

NCT03524326 COMPLETED

Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

Memorial Sloan Kettering Cancer Center

NCT04301011 TERMINATED

Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors

Turnstone Biologics, Corp.

NCT04925284 COMPLETED

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

Exelixis

NCT03894618 COMPLETED

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

Shattuck Labs, Inc.

NCT05452408 WITHDRAWN

Antitumor-B KAC PK Study

Medical College of Wisconsin

NCT04502888 TERMINATED

Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin

Shattuck Labs, Inc.

NCT04588038 TERMINATED

NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery

Hyunseok Kang, MD

NCT02381535 COMPLETED

Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin

National Cancer Institute (NCI)

NCT02113878 COMPLETED

Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck

Dana-Farber Cancer Institute

NCT04870840 COMPLETED

Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer

M.D. Anderson Cancer Center

NCT04713891 COMPLETED

A Study of KF-0210 in Advanced Solid Tumors Patients

Keythera Pharmaceuticals (Australia) Pty Ltd

NCT04160065 COMPLETED

Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers

TuHURA Biosciences, Inc.

NCT03028766 COMPLETED

WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer

University of Birmingham

NCT04925713 COMPLETED

IFx-Hu2.0 for the Treatment of Patients With Skin Cancer

TuHURA Biosciences, Inc.

NCT01847326 COMPLETED

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer

University of Chicago

NCT02020707 COMPLETED

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Mayo Clinic

NCT03641547 COMPLETED

M6620 Plus Standard Treatment in Oesophageal and Other Cancer

University of Oxford

NCT06357858 WITHDRAWN

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Case Comprehensive Cancer Center

NCT03292822 COMPLETED

Effects of (Licochalcone A) and Paclitaxel on Human Oral Squamous Cell Carcinoma Cell Line

Cairo University

NCT03621982 TERMINATED

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

ADC Therapeutics S.A.

NCT02164461 COMPLETED

Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer

Advaxis, Inc.

NCT05061537 TERMINATED

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Pfizer

NCT04714983 SUSPENDED

DNX-2440 for Resectable Colorectal Liver Metastasis

DNAtrix, Inc.

NCT04892875 WITHDRAWN

A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers

Jennifer Choe

NCT03452332 COMPLETED

Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

M.D. Anderson Cancer Center

NCT05729139 WITHDRAWN

Cemiplimab/Peg-Interferon-α in Advanced CSCC

Baptist Health South Florida

NCT03215810 COMPLETED

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

H. Lee Moffitt Cancer Center and Research Institute

NCT04572100 COMPLETED

Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer

University of Chicago

NCT01935921 COMPLETED

Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer

National Cancer Institute (NCI)

NCT02376699 TERMINATED

Safety Study of SEA-CD40 in Cancer Patients

Seagen Inc.

NCT03841110 COMPLETED

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

NCT05220748 WITHDRAWN

RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC

Rakuten Medical, Inc.

NCT03758781 COMPLETED

IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors

H. Lee Moffitt Cancer Center and Research Institute

NCT02890368 TERMINATED

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

Pfizer

NCT04413214 COMPLETED

Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic HNSCC (Non NPC): A Phase I Trial

Shanghai Jiao Tong University School of Medicine

NCT01332279 WITHDRAWN

Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

Fox Chase Cancer Center

NCT05472220 WITHDRAWN

Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma

Pamela Munster

NCT03517488 COMPLETED

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

Xencor, Inc.

NCT04596033 TERMINATED

TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy

Genocea Biosciences, Inc.

NCT02775812 COMPLETED

Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma

National Cancer Institute (NCI)

NCT03458117 COMPLETED

T-VEC in Non-melanoma Skin Cancer

University of Zurich

NCT03144778 COMPLETED

Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer

M.D. Anderson Cancer Center

NCT03333694 TERMINATED

Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)

Novartis Pharmaceuticals

NCT01711515 COMPLETED

Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer

National Cancer Institute (NCI)

NCT02464137 TERMINATED

HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer

University of Texas Southwestern Medical Center

NCT01249443 TERMINATED

Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection

AIDS Malignancy Consortium

NCT00966472 COMPLETED

Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC

Ottawa Hospital Research Institute

NCT03198130 COMPLETED

An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)

Regeneron Pharmaceuticals

NCT01254617 COMPLETED

Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer

National Cancer Institute (NCI)

NCT03575234 WITHDRAWN

Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer

Emory University

NCT01281852 COMPLETED

Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

National Cancer Institute (NCI)

NCT03652233 WITHDRAWN

Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Vanderbilt-Ingram Cancer Center

NCT01064921 COMPLETED

Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma

Ohio State University Comprehensive Cancer Center

NCT01017185 COMPLETED

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Takara Bio Inc.

NCT02277197 COMPLETED

Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

James J Lee

NCT02035527 COMPLETED

Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Ohio State University Comprehensive Cancer Center

NCT01440998 COMPLETED

Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

NCT00878995 COMPLETED

Testosterone for Treating Cachexia in Patients With Squamous Cell Carcinoma

The University of Texas Medical Branch, Galveston

NCT02993991 WITHDRAWN

Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity

University Health Network, Toronto

NCT00575952 COMPLETED

Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer

Gynecologic Oncology Group

NCT00903461 TERMINATED

Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma

University of Pittsburgh

NCT01283178 TERMINATED

Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC

Virginia Commonwealth University

NCT01921426 COMPLETED

A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck

Galera Therapeutics, Inc.

NCT01528137 TERMINATED

Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer

Stanford University

NCT02334319 TERMINATED

Ganetespib Window of Opportunity Study in Head and Neck Cancers

Emory University

NCT01115790 COMPLETED

A Phase 1 Study in Participants With Advanced Cancer

Eli Lilly and Company

NCT02666534 COMPLETED

Efficacy of AFL-assisted PDT in Microinvasive Squamous Cell Carcinoma

Dong-A University

NCT01334177 COMPLETED

TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck

University of Washington

NCT01208883 COMPLETED

A Feasibility Study On Continuous Adaptive [18f]Fdg-Pet-Guided Radiotherapy For Head and Neck Cancer

University Hospital, Ghent

NCT01728480 WITHDRAWN

Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy

Roswell Park Cancer Institute

NCT00906360 TERMINATED

Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck

National Cancer Institute (NCI)

NCT01637194 COMPLETED

Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer

Fox Chase Cancer Center

NCT00937300 WITHDRAWN

T-cell Based Immunotherapy for Head and Neck Cancer

Inge Marie Svane

Full Squamous Cell Carcinoma Pipeline

Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only